glp-1 prostate cancer Potential preventive properties of receptor agonists against cancer: a nationwide cohort study | Diabetologia Emerging Evidence Positions GLP-1 Receptor

Only 0.2% of hospitalized adults with type 2 diabetes were prescribed a GLP-1 receptor agonist

doi: 10.1093/cercor/bhaa294

The secondary endpoints were the percentage change in body weight from baseline to 48 weeks and the presence of weight reduction in 5%, 10%, and 15%

Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) increased slightly from September to December 2025 (+5.0%)

Additional well-designed, prospective studies are needed to confirm the potential benefit of GLP-1 receptor agonist treatment for patients with advanced CKD or ESKD." For further information: DOI: 10.1001/jamanetworkopen.2022.1169 Keywords: CKD, ESKD, GLP-1 receptor agonist, DPP-4 inhibitors, type 2 diabetes, JAMA Network Open, chronic kidney disease, end-stage kidney disease, National Health Insurance Research Database of Taiwan, MACCE, Mortality rate